Ibere Pharmaceuticals (IBER)
|Net Income (ttm)||n/a|
|Trading Day||June 22|
|Day's Range||9.67 - 9.71|
|52-Week Range||9.65 - 9.95|
PHILADELPHIA, May 28, 2021 /PRNewswire/ -- Ibere Pharmaceuticals (NYSE: IBER) (the "Company") today announced that it received a notice on May 25, 2021 from the New York Stock Exchange (the "NYSE") indi...
Ibere Pharmaceuticals (the "Company") announced today that it closed its initial public offering of 13,800,000 units at $10.00 per unit, which...
Ibere Pharmaceuticals, a blank check company formed by PIPV Capital targeting pharmaceutical or life science businesses, filed on Tuesday with the SEC to raise up to $100 million in an initial public of...
Ibere Pharmaceuticals has filed to go public with an IPO on the New York Stock Exchange (NYSE).
Ibere Pharmaceuticals is a blank check company whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Ibere Pharmaceuticals is targeting a large addressable market as total worldwide prescription drug sales lost due to patent expiration from 2020 through 2026 is expected to be approximately $252 billion, according to EvaluatePharma. Our management team has a combined track record of over 100 years of successfully identifying, ac... [Read more...]
|IPO Date |
Feb 26, 2021
|Stock Exchange |
|Ticker Symbol |